■循环肿瘤DNA(ctDNA)在肺癌新辅助治疗(NAT)中的价值仍存在争议。因此,我们进行了综述,以进一步研究ctDNA在接受NAT个体化管理的非小细胞肺癌(NSCLC)患者中的作用.
■搜索在线数据库(PubMed,Embase,WebofScience,科学直接,和Cochrane文库)进行评估ctDNA在预测复发中的价值,风险分层,NAT在非小细胞肺癌中的疗效。只有在过去的25年中发表的英文文章,1月1日之间,1998年11月30日,2023年,包括。此外,现就ctDNA在非小细胞肺癌中的应用作一简要综述。
■ctDNA是一种非侵入性和动态的方法,在未来的治疗指导中起着重要作用。此外,ctDNA成功预测了术前新辅助免疫治疗的效果,阳性检测与较低的主要病理反应或完全病理反应率密切相关。ctDNA的顺序测试可以作为指导治疗方案调整的次要指标。然而,这种方法的应用受到假阴性结果的限制,缺乏客观指标,和高成本。这些问题必须由研究人员来解决。
■ctDNA在NAT中具有强大的潜力,基于积极的初步研究。然而,它的广泛使用受到测试成本高的限制。未来需要进一步研究以探索其在风险分层和治疗指导中的价值。
UNASSIGNED: The value of circulating tumor DNA (ctDNA) in neoadjuvant therapy (NAT) for lung cancer remains controversial. Therefore, we conducted a review to further investigate the role of ctDNA in non-small cell lung cancer (NSCLC) patients undergoing NAT for individualized management.
UNASSIGNED: A search of online databases (PubMed, Embase, Web of Science, Science Direct, and Cochrane Library) was conducted to evaluate the value of ctDNA in predicting relapse, risk stratification, and efficacy of NAT in NSCLC. Only articles published in English within the last 25 years, between January 1st, 1998 and November 30th, 2023, were included. Additionally, the application of ctDNA in NSCLC is briefly reviewed.
UNASSIGNED: ctDNA is a non-invasive and dynamic method that plays an important role in future treatment guidance. Additionally, ctDNA successfully predicted the effect of neoadjuvant immunotherapy before surgery, and positive testing was strongly correlated with a lower major pathological response or complete pathological response rate. Sequential testing of ctDNA may serve as a secondary indicator to guide the adjustment of treatment programs. However, the application of this method has been limited by false negative results, a lack of objective indicators, and high costs. These issues must be addressed by researchers.
UNASSIGNED: ctDNA has strong potential in NAT, based on positive preliminary studies. However, its widespread use is limited by the high cost of testing. Further research is needed to explore its value in risk stratification and treatment guidance in the future.